The Possible Protective Effect of Cinnamic Acid on Ovalbumin-Induced Asthma in Mice


  • Haidar AL-Saffar Ministry of Health and Environment, Baghdad, Iraq.
  • Munaf H. Zalzala Department of Pharmacology and Toxicology, College of Pharmacy, University of Baghdad, Baghdad, Iraq.



Allergic asthma, airway inflammation, ovalbumin OVA, cinnamic acid (CA), chronic inflammation


Asthma is a chronic respiratory disorder in which immunological and structural cells play a role. The limits of conventional medicines necessitate the development of innovative therapeutic techniques for asthma. In the present study, we investigated the possible protective effect of cinnamic acid (CA) on ovalbumin-induced asthma in a mouse model. Sixty albino male mice BALB/c type weighing (20-30) grams were chosen at random and divided into five groups each one contains 12 animal: Group I: PBS/liquid paraffin control. Group II: asthma model group. Group III: cinnamic acid control group; mice received cinnamic acid (50 mg/kg) in liquid paraffin orally by gavage. Group IV: asthma model / group of (25 mg / kg) cinnamic acid; mice received (25 mg/kg) in liquid paraffin orally by gavage. Group V:  asthma/ (50 mg/kg) cinnamic acid group; mice received cinnamic acid (50 mg/kg) in liquid paraffin orally by gavage. The experiment continued for 14 days. On day 15, broncho-alveolar lavage fluid, blood and lung tissue was collected. Total cell count, tissue TNF- α, IL -33, and serum IgE increased considerably after sensitization to ovalbumin (OVA), while GSH levels decreased significantly. On the other hand, administration of cinnamic acid in (25mg and 50mg/kg) has significantly decreased total WBC count, tissue TNF- α, IL -33, and serum IgE results, and a significant increase on GSH results. These findings suggest that cinnamic acid has a protective effect against OVA-induced allergic asthma in mice, possibly through its antioxidant activity and inhibitory activity on some proliferative modulating enzymes.


Kudo M, Ishigatsubo Y, Aoki I. Pathology of asthma. Frontiers in microbiology. 2013; 4:263.

Ahmed ZH, Zalzala MH. Study the Anti-Asthmatic Activity of Guggulsterone in Ovalbumin-Induced Asthma in Rat. Iraqi J Pharm Sci. 2021; 30(2):64–70.

Jasim AL, Saleh ES, Ali MNA. Evaluating the Clinical Outcomes of Three Medication Regimens for Treating a Sample of Iraqi Persistent Asthmatic Patients. Iraqi J Pharm Sci.2020; 29(1):154–65.

Global initiative for asthma (GINA). 2006.

Zosky, G. R. and Sly, P. D., Animal models of asthma. Clin. Exp. Allergy 37, 973-988, (2007).

Hough, K. P., Curtiss, M. L., Blain, T. J., Liu, R. M., Trevor, J., Deshane, J. S., & Thannickal, V. J. (2020). Airway Remodeling in Asthma. In Frontiers in Medicine (Vol. 7). Frontiers Media S.A.

Luana Dalbem Rocha, Mariana Costa Monteiro & Anderson Junger Teodoro, Anticancer Properties of Hydroxycinnamic Acids -A Review, Cancer and Clinical Oncology; Vol. 1, No. 2; 2012 ISSN 1927-4858 E-ISSN 1927-4866.

Hesham R. El-Seedi, Eman A. Taher, k, Bassem Y. Sheikh, Shazia Anjum, Hydroxycinnamic Acids: Natural sources, biosynthesis, possible biological activities, and roles in Islamic medicine, Studies in Natural Products Chemistry, Vol. 55.

De, P.; Baltas, M.; Bedos-Belval, F. Cinnamic Acid Derivatives as Anticancer Agents-A Review Current Medicinal Chemistry, Volume 18, Number 11, 2011, pp. 1672-1703(32).

Schroeder WG, Mitrescu LM, Hart ML, Unnithan R, Gilchrist JM, Smith EE, et al. Flexible low-cost system for small animal aerosol inhalation exposure to drugs, proteins, inflammatory agents, and infectious agents. Biotechniques. 2009; 46(3):1–6.

Kianmehr, M., Ghorani, V., & Boskabady, M. H. (2016). Animal model of asthma, various methods and measured parameters, a methodological review. Iranian Journal of Allergy, Asthma and Immunology, 15(6), 445–465.

Reddy AT, Lakshmi SP, Reddy RC. Murine model of allergen induced asthma. J Vis Exp. 2012 ;( 63):1–8.

Kim DI, Song MK, Lee K. Comparison of asthma phenotypes in OVA-induced mice challenged via inhaled and intranasal routes. BMC Pulm Med. 2019; 19(1):1–11.

Kumar, R. K., Herbert, C. and Foster, P. S. (2008). The ‘classical’ ovalbumin challenge model of asthma in mice. Curr. Drug Targets 9, 485-494.

Byard, R.W.; Musgrave, I.; Maker, G.; Bunce, M. What risks do herbal products pose to the Australian community? Med. J. Aust. 2017, 206, 86–90.

Sozzani S, Del Prete A, Bosisio D. Dendritic cell recruitment and activation in autoimmunity. J Autoimmune. 2017 Dec; 85:126-140.

Szwajgier, D.; Pielecki, J.; Targonski, Z. Antioxidant activities of cinnamic and benzoic acid derivatives. Acta Sci. Pol., Technol. Aliment., 2005, 4(2), 129-42.

Ruwizhi, N., & Aderibigbe, B. A. (2020). Cinnamic acid derivatives and their biological efficacy. International Journal of Molecular Sciences, 21(16), 1–36.

Mims, JW. Asthma: Definitions and pathophysiology. Int Forum Allergy Rhinol. 2015; 5(April):S2–6.

Fahy J V. Type 2 inflammation in asthma-present in most, absent in many. Nat Rev Immunol [Internet]. 2015; 15(1):57–65.